These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17354472)
1. [Activation of innate and specific immune responses in hemolytic uremic syndrome (HUS)-patients]. Palermo MS; Fernandez GC; Ramos MV; Bentancor L; Fernandez Brando R; Dran GI; Isturiz MA Medicina (B Aires); 2006; 66 Suppl 3():16-21. PubMed ID: 17354472 [TBL] [Abstract][Full Text] [Related]
2. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302 [TBL] [Abstract][Full Text] [Related]
3. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
4. Treatment of typical (enteropathic) hemolytic uremic syndrome. Bitzan M; Schaefer F; Reymond D Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636 [TBL] [Abstract][Full Text] [Related]